Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Susana M. Campos, MD, MPH


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director of Clinical Pathways, Division of Gynecologic Oncology
  • Director of Educational Initiatives, Division of Gynecologic Oncology
  • Institute Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gynecologic oncology

Contact Information

  • Appointments(617) 632-2175
  • Office Phone Number617-632-5269
  • Fax617-632-3479

Bio

Dr. Campos received her MD from Georgetown University in 1992, and then completed residency training at Georgetown Medical Center. Between 1995 and 1998, she completed a fellowship in hematology-oncology at Brigham and Women's Hospital, in Boston, and in 2000 received her MPH from Harvard Medical School. She serves on committees for the American Society of Clinical Oncology, the Gynecological Oncology Group, and the National Comprehensive Cancer Network. She is board-certified in internal medicine, oncology, and hematology.

Board Certification:

  • Hematology, 2003
  • Internal Medicine, 1997
  • Medical Oncology, 1999

Fellowship:

  • Brigham and Women's Hospital
  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Georgetown University Medical Center, Internal Medicine

Medical School:

  • Georgetown University School of Medicine

Research

Novel Therapies in Breast and Gynecological Cancers

Our research interests center on the clinical application of novel therapies - including epidermal growth factor receptor (EGFR) inhibitors, angiogenesis inhibitors, novel cytotoxic therapies, and hormonal agents - in breast and gynecological cancers. The EGFR superfamily is an attractive therapeutic target because it is commonly overexpressed in women's cancers, it regulates vital cellular processes, and it seems to be a negative prognostic indicator. Clinical trials focusing on novel therapies for breast, ovarian, and endometrial cancer are an important area of our research. Past trials have included (1) a comparison of exemestane versus anastrozole in postmenopausal women, (2) the role of D-99 and Herceptin in the management of metastatic breast cancer, (3) the role of CI-1033 given alone in advanced ovarian cancer, and (4) the role of CI-1033 in the management of advanced breast cancer. Current active trials include (1) the role of oral irinotecan in metastatic breast cancer, (2) a phase I trial of DOXIL/ Iressa in patients with gynecological malignancies and metastatic breast cancer, and (3) a retrospective review of newly diagnosed premenopausal women with endometrial cancer. Current projects include the establishment of a research program in endometrial cancer with specific attention to the adjuvant management of high-risk and metastatic disease. We are exploring ideas that include the role of aromatase inhibitors and Cox 2 inhibitors in the management of advanced endometrial cancer, the role of three-drug combinations as adjuvant therapy in the management of endometrial cancer, and the role of anti-VEGF molecules with cytotoxic therapy in advanced gynecological malignancies. Other research interests include the adjuvant management of advanced and poor histological types of endometrial cancer, new agents for metastatic endometrial cancers, and an epidemiological study of young premenopausal women with endometrial cancer.

Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms. Am J Surg Pathol. 2021 Jul 15.
View in: PubMed

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 Jul 06.
View in: PubMed

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 May 10; 39(14):1531-1539.
View in: PubMed

Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 May; 161(2):581-586.
View in: PubMed

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 12; 86(6):815-827.
View in: PubMed

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in: PubMed

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020 06; 18(6):660-666.
View in: PubMed

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584.
View in: PubMed

Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 11 01; 17(11):1374-1391.
View in: PubMed

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
View in: PubMed

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
View in: PubMed

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
View in: PubMed

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 01; 17(1):64-84.
View in: PubMed

Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb; 16(2):170-199.
View in: PubMed

Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
View in: PubMed

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):92-120.
View in: PubMed

Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
View in: PubMed

Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
View in: PubMed

Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Nov; 13(11):1321-31.
View in: PubMed

Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in: PubMed

Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):395-404; quiz 404.
View in: PubMed

Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
View in: PubMed

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
View in: PubMed

Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):248-80.
View in: PubMed

Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol. 2013 Nov; 131(2):464-6.
View in: PubMed

Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):320-43.
View in: PubMed

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
View in: PubMed

Securing discharge follow-up appointments in a women's cancer program. J Clin Oncol. 2012 Dec; 30(34_suppl):81.
View in: PubMed

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in: PubMed

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
View in: PubMed

Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
View in: PubMed

Antimitotic inhibitors. Hematol Oncol Clin North Am. 2012 Jun; 26(3):607-28, viii-ix.
View in: PubMed

Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
View in: PubMed

Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in: PubMed

Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging. 2011 Jun 15; 11:67-9.
View in: PubMed

The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in: PubMed

Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072.
View in: PubMed

Cervical cancer. J Natl Compr Canc Netw. 2010 Dec; 8(12):1388-416.
View in: PubMed

Cervical cancer screening. J Natl Compr Canc Netw. 2010 Dec; 8(12):1358-86.
View in: PubMed

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in: PubMed

A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010; 2010:149362.
View in: PubMed

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in: PubMed

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in: PubMed

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
View in: PubMed

Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
View in: PubMed

Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531.
View in: PubMed

A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
View in: PubMed

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in: PubMed

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in: PubMed

Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 2008 Oct; 26(8):757-68.
View in: PubMed

Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 Sep; 19 Suppl 7:vii266-72.
View in: PubMed

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
View in: PubMed

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in: PubMed

Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
View in: PubMed

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
View in: PubMed

Cervical cancer screening. J Natl Compr Canc Netw. 2008 Jan; 6(1):58-82.
View in: PubMed

Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intervenous and intraperitoneal desensitizations in 413 cases. 2008; 26(ASCO 2008):A:5526.

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. 2008; 26(ASCO 2008):A:5528.

Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36.
View in: PubMed

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008; 26(ASCO 2008):A: 5523.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24.
View in: PubMed

Integrative decisions in rectal cancer. Ann Oncol. 2007 Jul; 18 Suppl 9:ix127-31.
View in: PubMed

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarin and mullerian cancers. 2007; 25(ASCO 2007):A:5517.

Chemotherapy and radiation therapy UPSC. 2007; 25(ASCO 2007):A:5535.

A multimodality approach to localized rectal cancer. Ann Oncol. 2006 Sep; 17 Suppl 10:x129-34.
View in: PubMed

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
View in: PubMed

Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in: PubMed

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in: PubMed

Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62.
View in: PubMed

Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
View in: PubMed

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. 2006; 24(ASCO 2006):A:5020.

Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractoy gynecological malignancies or metastatic breast cancer. 2006; 24(ASCO 2006):A:5085.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16.
View in: PubMed

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
View in: PubMed

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005 Aug 20; 23(24):5597-604.
View in: PubMed

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
View in: PubMed

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
View in: PubMed

A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
View in: PubMed

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. J Clin Oncol. 2005 Jun; 23(16_suppl):562.
View in: PubMed

Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
View in: PubMed

A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies. 2005; 23(ASCO 2005):A:5010.

Long-acting octreotide (Sandostatin LAR Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. 2005; 23(ASCO 2005):A:5191.

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. 2005; 23(ASCO 2005):A:562.

Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005 Jan; 96(1):10-8.
View in: PubMed

Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecological malignancies. 2005; 23(ASCO 2005):A:5090.

Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat. 2005; 89 Suppl 1:S1-7.
View in: PubMed

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
View in: PubMed

Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30.
View in: PubMed

Cervical cancer screening clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):570-87.
View in: PubMed

A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5054.
View in: PubMed

A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. J Clin Oncol. 2004 Jul 15; 22(14_suppl):628.
View in: PubMed

A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
View in: PubMed

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
View in: PubMed

A phase II study of fixed dose-rate gemcitabine in patients with relapsed Mullerian tumors. 2004; 22(ASCO 2004):A:5151.

A comparative study of exemestane versus anastroxole in post-metopausal breast cancer subjects aith visceral disease. 2004; 22(ASCO 2004):A:628.

Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004; 9(2):126-36.
View in: PubMed

A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004; 22(ASCO 2004):A:5054.

Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
View in: PubMed

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
View in: PubMed

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in: PubMed

Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. 2003; 22(ASCO 2003):A:1872.

Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer. 2003; 22(ASCO 2003):A:3111.

Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
View in: PubMed

Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003; 8 Suppl 2:10-6.
View in: PubMed

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
View in: PubMed

The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol. 2002 Jun; 29(3 Suppl 8):7-12.
View in: PubMed

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9.
View in: PubMed

TLC D99 (D,Myocet) Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. 2002; 21(ASCO 2002):A:216.

Multicenter phase II study of trastuzumab (Herceptin;H) and vinorelbine (Navelbine;N) as first-line therapy for HER2 overexpressing metastic breast cancer (HER2+MBC). 2002; 21(ASCO 2002):A:211.

A phase I of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). 2002; 21(ASCO 2002):A:1840.

A phase I trial of continual sequential oral etoposide and infusional topotecan. 2002; 21(ASCO2002):A:2168.

A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
View in: PubMed

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
View in: PubMed

Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. 2001; 20(ASCO 2001):A:846.

Preliminary Cardiac Safety and Efficacy Data from Phase I/II Trial of TLC D-99 (D-99) and Trastuzumab (T) in patients withs locally advanced or Metastatic Breast CAncer (LABC/MBC). 2001; 20(ASCO 2001):A:180.

A Phase II and Pharmacokinetic/Dynamic study of Doxil and weekly Paclitaxel chemotherapy for Rucurrent Mullerian Tumors. 2001; 20(ASCO 2001):A:2524.

A Phase II and Pharmacokinetic/Dynamic Studyof Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Mullerian Tumors. 2000; 19(ASCO 2000):A:1623.

A Phase I/II Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recuurent Mullerian Tumors. 2000; 19(ASCO 2000):A:1552.

Herceptin and Vinorelbine for HER-2 Positive Metastatic Breast Cancer: A Phase II Study. 2000; 19(ASCO 2000):A:392.

Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.

A Phase I Study Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. 2000; 19(ASCO 2000):A:444.

Magnetic resonance angiography in the diagnosis of a case of giant cell arteritis manifesting as scalp necrosis. Arch Dermatol. 1999 Jul; 135(7):769-71.
View in: PubMed

A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer(ROC)(Meeting abstract). 1999; (ASCO 1999):A:1434.

Images in clinical medicine. Spigelian hernia. N Engl J Med. 1997 Apr 17; 336(16):1149.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top